AKR1D1*36 C&gt;T (rs1872930) allelic variant is associated with variability of the CYP2C9 genotype predicted pharmacokinetics of ibuprofen enantiomers – a pilot study in healthy volunteers

Kapedanovska Nestorovska, Aleksandra; Jakjovski, Krume; Naumovska, Zorica; Sterjev, Zoran; Geskovska, Nadica Matevska; Mladenovska, Kristina; Suturkova, Ljubica; Dimovski, Aleksandar

doi:10.2478/acph-2019-0032

Abstract

The relative contribution of CYP2C9 allelic variants to the pharmacokinetics (PK) of ibuprofen (IBP) enantiomers has been studied extensively, but the potential clinical benefit of pharmacogenetically guided IBP treatment is not evident yet. The role of AKR1D1*36C>T (rs 1872930) allelic variant in interindividual variability of CYP450 mediated drug metabolism was recently elucidated. A total of 27 healthy male subjects, volunteers in IBP single-dose two-way cross-over bioequivalence studies were genotyped for CYP2C9*2, CYP2C9*3 and AKR1D1*36 polymorphisms. The correlation between CYP2C9 and AKR1D1 genetic profile and the PK parameters for S-(+) and R-(−)-IBP was evaluated. Remarkable changes in the PK values pointing to reduced CYP2C9 enzyme activity were detected only in the CYP2C9*2 allelic variant carriers. Statistically significant association between the AKR1D1*36 allele and the increased IBP metabolism (low AUC_0-t and _0–∞, high Cl_tot and short t_max values for both enantiomers) was observed in subjects carrying the CYP2C9 *1/*3 or CYP2C9*1/*1 genotype. The clinical value of concomitant CYP2C9 and AKR1D1 genotyping has to be further verified.

References

1. K. D. Rainsford, Fifty years since the discovery of ibuprofen, Inflammopharmacol.19 (2011) 293–297; https://doi.org/10.1007/s10787-011-0103-710.1007/s10787-011-0103-722120888
Search in Google Scholar Back to article
2. M. De Martino, A. Chiarugi, A. Boner, G. Montini and L. de’ Angelis, Working towards an appropriate use of ibuprofen in children: An evidence-based appraisal, Drugs77 (2017) 1295–1311; https://doi.org/10.1007/s40265-017-0751-z.10.1007/s40265-017-0751-z552947628597358
Search in Google Scholar Back to article
3. H. Hao, G. Wang and Sun, Enantioselective pharmacokinetics of ibuprofen and involved mechanisms, Drug Metab. Rev. 37 (2005) 215–234; https://doi.org/10.1081/DMR-20004799910.1081/DMR-200047999
Search in Google Scholar Back to article
4. K. D. Rainsford, Ibuprofen: pharmacology, efficacy and safety, Inflammopharmacol.17 (2009) 275–342; https://doi.org/10.1007/s10787-009-0016-x10.1007/s10787-009-0016-x19949916
Search in Google Scholar Back to article
5. G. Ding, Y. Liu, J. Sun, Y. Takeuchi, T. Toda, T. Hayakawa, S. Fukushima, S. Kishimoto, W. Lin and Inotsume, Effect of absorption rate on pharmacokinetics of ibuprofen in relation to chiral inversion in humans, J. Pharm. Pharmacol.59 (2007) 1509–13; https://doi.org/10.1211/jpp.59.11.000710.1211/jpp.59.11.000717976261
Search in Google Scholar Back to article
6. T. J. Legg, A. L. Laurent, R. Leyva and D. Kellstein, Ibuprofen sodium is absorbed faster than standard Ibuprofen tablets: results of two open-label, randomized, crossover pharmacokinetic studies, Drugs R.D.14 (2014) 283–290; https://doi.org/10.1007/s40268-014-0070-810.1007/s40268-014-0070-8426981825395311
Search in Google Scholar Back to article
7. F. Jamali and D. R. Brocks, The Pharmacokinetics of Ibuprofen in Humans and Animals, in Ibuprofen (Ed. K. Rainsford), 1^st ed., John Wiley & Sons, New York 2015, pp. 81–131; https://doi.org/10.1002/9781118743614.ch410.1002/9781118743614.ch4
Search in Google Scholar Back to article
8. S. C. Tan, B. K. Patel, S. H. Jackson, C. G. Swift and A. J. Hutt, Stereoselectivity of ibuprofen metabolism and pharmacokinetics following the administration of the racemate to healthy volunteers, Xenobiotica32 (2002) 683–697; https://doi.org/10.1080/0049825021014299410.1080/0049825021014299412296989
Search in Google Scholar Back to article
9. J. Kirchheiner, I. Meineke, G. Freytag, C. Meisel, I. Roots and J. Brockmöller, Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2, Clin. Pharmacol. Ther.72 (2002) 62–75; https://doi.org/10.1067/mcp.2002.12572610.1067/mcp.2002.12572612152005
Search in Google Scholar Back to article
10. S. Y. Chang, W. Li, S. C. Traeger, B. Wang, D. Cui, H. Zhang, B. Wen and A. D. Rodrigues, Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(−)-ibuprofen hydroxylation in vitro, Drug Metab. Dispos. 36 (2008) 2513–2522; https://doi.org/10.1124/dmd.108.02297010.1124/dmd.108.02297018787056
Search in Google Scholar Back to article
11. A. D. Rodrigues, Impact of CYP2C9 genotype on pharmacokinetics: Are all cyclooxygenase inhibitors the same? Drug Metab. Dispos.33 (2005) 1567–1575; https://doi.org/10.1124/dmd.105.00645210.1124/dmd.105.006452
Search in Google Scholar Back to article
12. F. Mazhar, N. Haider, J. Sultana, S. Akram and Y. Ahmed, Prospective study of NSAIDs prescribing in Saudi Arabia: Cardiovascular and gastrointestinal risk in patients with diabetes mellitus, Int. J. Clin. Pharmacol. Ther.56 (2018) 64–71; https://doi.org/10.5414/CP20307110.5414/CP203071
Search in Google Scholar Back to article
13. O. O. Moninuola, W. Milligan, P. Lochhead and H. Khalili, Systematic review with meta-analysis: association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn’s disease and ulcerative colitis exacerbation, Aliment. Pharmacol. Ther.47 (2018) 1428–1439; https://doi.org/10.1111/apt.1460610.1111/apt.14606
Search in Google Scholar Back to article
14. A. Pilotto, D. Seripa, M. Franceschi, C. Scarcelli, D. Colaizzo, E. Grandone, V. Niro, A. Andriulli, G. Leandro, F. Di Mario and B. Dallapiccola, Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms, Gastroenterology133 (2007) 465–471; https://doi.org/10.1124/dmd.105.00645210.1124/dmd.105.006452
Search in Google Scholar Back to article
15. G. S. Pazhayattil and A. C. Shirali, Drug-induced impairment of renal function, Int. J. Nephrol. Renovasc. Dis.7 (2014) 457–468, https://doi.org/10.2147/IJNRD.S3974710.2147/IJNRD.S39747
Search in Google Scholar Back to article
16. G. V. Rollason, C. F. Samer, Y. Daali and J. A. Desmeules, Prediction by pharmacogenetics of safety and efficacy of non-steroidal anti-inflammatory drugs: a review, Curr. Drug Metab.15 (2014) 326–343; https://doi.org/10.2174/138920021566614020221445410.2174/1389200215666140202214454
Search in Google Scholar Back to article
17. U. Yasar, S. Lundgren, E. Eliasson, A. Bennet, B. Wiman, U. de Faire and A. Rane, Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms, BiochemBiophysResCommun.299 (2002) 25–28; https://doi.org/10.1016/S0006-291X(02)02592-510.1016/S0006-291X(02)02592-5
Search in Google Scholar Back to article
18. W. C. Speed, S. P. Kang, D. P. Tuck, L. N. Harris and K. K. Kidd, Global variation in CYP2C8-CYP2C9 functional haplotypes, Pharmacogenomics J.9 (2009) 283–290; https://doi.org/10.1038/tpj.2009.1010.1038/tpj.2009.10278240519381162
Search in Google Scholar Back to article
19. T. S. Tracy, A. S. Chaudhry, B. Prasad, K. E. Thummel, E. G. Schuetz, X. B. Zhong, Y. C. Tien, H. Jeong, X. Pan, L. M. Shireman, J. Tay-Sontheimer and Y. S. Lin, Interindividual variability in cytochrome P450-mediated drug metabolism, Drug Metab. Dispos. 44 (2016) 343–351; https://doi.org/10.1124/dmd.115.06790010.1124/dmd.115.067900476738626681736
Search in Google Scholar Back to article
20. J. Kirchheiner and J. Brockmöller, Clinical consequences of cytochrome P450 2C9 polymorphisms, Clin. Pharmacol. Ther. 77 (2005) 1–16; https://doi.org/10.1016/j.clpt.2004.08.00910.1016/j.clpt.2004.08.00915637526
Search in Google Scholar Back to article
21. A. S. Chaudhry, R. K. Thirumaran, K. Yasuda, X. Yang, Y. Fan, S. C. Strom and E. G. Schuetz, Genetic variation in aldo-keto reductase 1D1 (AKR1D1) affects the expression and activity of multiple cytochrome P450s, Drug Metab. Dispos. 41 (2013) 1538–1547; https://doi.org/10.1124/dmd.113.05167210.1124/dmd.113.051672416200523704699
Search in Google Scholar Back to article
22. T. M. Penning, The aldo-keto reductases (AKRs): Overview, Chem. Biol. Interact.234 (2015) 236–246; https://doi.org/10.1016/j.cbi.2014.09.02410.1016/j.cbi.2014.09.024438879925304492
Search in Google Scholar Back to article
23. N. Nakov, L. Bogdanovska, J. Acevska, J. Tonic-Ribarska, R. Petkovska A. Dimitrovska, L. Kasabova and D. Svinarov, High-throughput HPLC-MS/MS method for quantification of ibuprofen enantiomers in human plasma: Focus on investigation of metabolite interference, J. Chromatogr. Sci.54 (2016) 1820–1826; https://doi.org/10.1093/chromsci/bmw16610.1093/chromsci/bmw16627733482
Search in Google Scholar Back to article
24. K. Jakovski, A. Kapedanovska Nestorovska, N. Labacevski and A. J. Dimovski, Characterization of the most common CYP2C9 and CYP2C19 allelic variants in the population of R. Macedonia, Pharmazie68 (2013) 893–898, https://doi.org/10.1691/ph.2013.3579
Search in Google Scholar Back to article
25. A. Kapedanovska Nestorovska, K. Jakovski, Z. Naumovska, Z. Sterjev, N. Matevska Geskovska, A. J. Dimovski and Lj. Suturkova, Allele frequency and genotype distribution of aldo keto reductase 1D1 (AKR1D1) rs1872930 genetic variant in a Macedonian population, Maced. Pharm. Bull. 64 (2018), in press.10.33320/maced.pharm.bull.2018.64.01.005
Search in Google Scholar Back to article
26. C. Martínez, E. García-Martín, G. Blanco, F. J. Gamito, J. M. Ladero and J. A. Agúndez, The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects, Br. J. Clin. Pharmacol.59 (2005) 62–69; https://doi.org/10.1111/j.1365-2125.2004.02183.x10.1111/j.1365-2125.2004.02183.x188495915606441
Search in Google Scholar Back to article
27. E. García-Martín, C. Martínez, B. Tabarés, J. Frías and J. A. Agúndez, Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms, Clin. Pharmacol. T her.76 (2004) 119–127; https://doi.org/10.1016/j.clpt.2004.04.00610.1016/j.clpt.2004.04.00615289789
Search in Google Scholar Back to article
28. D. Ochoa, R. Prieto-Pérez, M. Román, M. Talegón, A. Rivas, G. Galicia, F. Abad-Santos and T. Cabaleiro, Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers, Pharmacogenomics16 (2015) 939–948; https://doi.org/10.2217/pgs.15.4010.2217/pgs.15.4026122864
Search in Google Scholar Back to article
29. R. López-Rodríguez, J. Novalbos, S. Gallego-Sandín, M. Román-Martínez, J. Torrado, J. P. Gisbert and F. Abad-Santos, Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers, Pharmacol. Res.58 (2008) 77–84; https://doi.org/10.1016/j.phrs.2008.07.00410.1016/j.phrs.2008.07.00418694831
Search in Google Scholar Back to article
30. M. Karazniewicz-Lada, M. Luczak and F. Glowka, Pharmacokinetic studies of enantiomers of ibuprofen and its chiral metabolites in humans with different variants of genes coding CYP2C8 and CYP2C9 isoenzymes, Xenobiotica39 (2009) 476–485; https://doi.org/10.1080/0049825090286270510.1080/0049825090286270519480553
Search in Google Scholar Back to article
31. A. D. Rodrigues and T. H. Rushmore, Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences, Curr. Drug Metab.3 (2002) 289–309; https://doi.org/10.2174/138920002333752210.2174/138920002333752212083322
Search in Google Scholar Back to article
32. D. H. Solomon, M. E. Husni, P. A. Libby, N. D. Yeomans, A. M. Lincoff, T. F. Lϋscher, V. Menon, D. M. Brennan, L. M. Wisniewski, S. E. Nissen and J. S. Borer, The risk of major NSAID toxicity with celecoxib, ibuprofen, or naproxen: A secondary analysis of the PRECISION trial, Am. J. Med.130 (2017) 1415–1422.e4; https://doi.org/10.1016/j.amjmed.2017.06.02810.1016/j.amjmed.2017.06.02828756267
Search in Google Scholar Back to article
33. N. Moore and J. M. Scheiman, Gastrointestinal safety and tolerability of oral non-aspirin over-the-counter analgesics, Postgrad. Med.130 (2018) 188–199; https://doi.org/10.1016/j.amjmed.2017.06.0210.1080/00325481.2018.1429793
Search in Google Scholar Back to article

AKR1D1*36 C>T (rs1872930) allelic variant is associated with variability of the CYP2C9 genotype predicted pharmacokinetics of ibuprofen enantiomers – a pilot study in healthy volunteers

Abstract

Paradigm

My account